14-day Premium Trial Subscription Try For FreeTry Free

Biotech's Blockbuster Week: 3 Stocks to Watch

05:32pm, Friday, 13'th Jan 2023 Zacks Investment Research
In a strong week for the market, biotech dominated. Today we will cover 3 promising stocks in the space.
Catalyst Pharmaceuticals and Harmony Bioscience each have a single product in their respective pipelines, and both show incredible promise.

Is Most-Watched Stock Catalyst Pharmaceuticals, Inc. (CPRX) Worth Betting on Now?

02:00pm, Tuesday, 10'th Jan 2023 Zacks Investment Research
Catalyst (CPRX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Catalyst (CPRX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
As last year's bear market spills over into 2023, breakout index stocks like CAT, BOX, AZN and ELF stock show resilience. The post Which Stocks Show Thick Skin As Bears Sink Fangs Into New Year?

Sector Leaders End Tough Year With Thin Ranks

03:04pm, Friday, 30'th Dec 2022
New Year starts with just three top stocks that meet IBD Sector Leaders' stringent criteria: Super Micro Computer, KLA and Catalyst Pharma. The post Sector Leaders End Tough Year With Thin Ranks appea

Biotech: 3 Profitable Bios Worth Owning

07:19pm, Wednesday, 28'th Dec 2022 Zacks Investment Research
The biotechnology space can be a difficult area to generate profits. Drugs take years to develop and often fail FDA approval. Today we will look at three top biotech stocks that are very profitable an

Biotech: 3 Profitable Bios Worth Owning

03:22pm, Wednesday, 28'th Dec 2022
The biotechnology space can be a difficult area to generate profits. Drugs take years to develop and often fail FDA approval.
These leading biotech stocks have had a good quarter and some may have room to run, while for others it's time to ring the register. The post Biotech And Medical Stocks Leading Performers As 2022 Draw
HC Wainwright & Co. has decided to maintain its Buy rating of Catalyst Pharmaceuticals (NASDAQ:CPRX) and raise its price target from $18.00 to $24.00. Shares of Catalyst Pharmaceuticals are trading up
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
Acquisition Expands The Company’s Commercial Portfolio With An Established U.S. Marketed Product

This Growth Stock's Jaw-Dropping Run-Up Is Smashing Tesla's

09:30pm, Friday, 16'th Dec 2022 The Motley Fool
It's practically printing cash, and even more is on the way.
It's practically printing cash, and even more is on the way.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE